Nogo-66(1-40) antagonist peptide

SIGMA/N7161 - ≥84% (HPLC)

Synonym: NEP (1-40)

Empirical Formula (Hill Notation): C₂₀₄H₃₂₂N₅₆O₆₄ · xC₂HF₃O₂
Molecular Weight: 4583.08 (free base basis)
MDL Number: MFCD06411437
Linear Formula: C₂₀₄H₃₂₂N₅₆O₆₄ · xC₂HF₃O₂
Product Type: Chemical

Catalog Number	PKG Qty.	Price


45-N7161-1MG	1 mg	$637.00 1/EA	Add To Favorites

This image is provided for informative purposes only and does not represent an actual product label. It should not be used as a substitute for official product labeling.

Properties
Descriptions
Safety Info.
Basic Data

assay	≥84% (HPLC)
color	white
form	lyophilized solid
InChI	1S/C206H324N56O65/c1-23-104(15)163(258-169(292)109(20)226-174(297)126(59-67-148(210)272)240-201(324)166(107(18)26-4)261-199(322)160(101(9)10)255-153(277)92-223-171(294)120(41-30-33-75-207)230-186(309)138(86-115-51-57-119(271)58-52-115)249-202(325)165(106(
InChI key	OLEKMOOQFWTQGD-SJQNMCRDSA-N
Quality Level	100
SMILES string	[nH]1cnc(c1)C[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)C)CCCNC(=N)N)[C@H](CC)C)Cc6ccc(cc6
solubility	H₂O: 1 mg/mL
storage temp.	−20°C
UniProt accession no.	Q9NQC3

Amino Acid Sequence:	Arg-Ile-Tyr-Lys-Gly-Val-Ile-Gln-Ala-Ile-Gln-Lys-Ser-Asp-Glu-Gly-His-Pro-Phe-Arg-Ala-Tyr-Leu-Glu-Ser-Glu-Val-Ala-Ile-Ser-Glu-Glu-Leu-Val-Gln-Lys-Tyr-Ser-Asn-Ser-NH2
Application:	Nogo-66(1-40) antagonist peptide has been used as a Nogo-66 receptor antagonist peptide: • to study the preliminary therapeutic effect after inhibition of Nogo-A in the cauda equina compression (CEC) model • to determine the effects of Nogo-A/NgR1 on autophagic activation • to study its role in Nogo-B mediated axonal branching using Schwann cells and sensory neurons of mice
Biochem/physiol Actions:	Myelin-derived axon outgrowth inhibitors, such as Nogo, may account for the lack of axonal regeneration in the central nervous system (CNS) after trauma in adult mammals. Nogo-66 can inhibit axonal outgrowth through an axonal Nogo-66 receptor (NgR). Competitive antagonists of NgR derived from amino-terminal peptide fragments of Nogo-66. The Nogo-66(1 40) antagonist peptide (NEP1 40) blocks Nogo-66 or CNS myelin inhibition of axonal outgrowth in vitro, demonstrating that NgR mediates a significant portion of axonal outgrowth inhibition by myelin. Intrathecal administration of NEP1 40 to rats with mid-thoracic spinal cord hemisection results in significant axon growth of the corticospinal tract, and improves functional recovery. Thus, Nogo-66 and NgR have central roles in limiting axonal regeneration after CNS injury, and NEP1-40 provides a potential therapeutic agent.
Biochem/physiol Actions:	Nogo-66(1-40) promotes axonal regeneration; it blocks effects of axon outgrowth inhibitors such as Nogo66.
Legal Information:	Sold under a non-exclusive license. For research use only, and not for diagnostic or therapeutic use or for use in humans.
Packaging:	1 mg in glass bottle

RIDADR	NONH for all modes of transport
WGK Germany	WGK 3
Flash Point(F)	Not applicable
Flash Point(C)	Not applicable

Purity	≥84% (HPLC)
Storage Temp.	−20°C
UNSPSC	12352202

To Order From a Quote